
LifeArc Ventures is the venture investment arm of LifeArc, a self-funded medical research charity. It invests in early-stage, science-led therapeutics and healthtech companies from seed to Series B, providing scientific insight, advice, and venture funding, with financial returns reinvested into LifeArc's charitable mission.
48% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 5 prior). Their most common stage is series-a (55% of deals). Average disclosed round size is $62.6M (across 20 rounds with reported amounts).
Portfolio
25
Fund Size
—
Top Stage
Series A
Last 12 Mo
5
Team
Dr Ian Gilham
Chair of Board of Trustees
Sam Barrell
Chief Executive Officer (CEO)
Stéphane Maikovsky
Deputy Chief Executive Officer and Chief Financial Officer
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| Series A | $115M | Jun 2026 | |
| Series A | — | May 2026 | |
| Series B | — | Jan 2026 | |
| Series A | $61M | Jan 2026 | |
| RRq Biotechnology Ltd | Series A | $115M | Jan 2026 |
| Series B | $130M | May 2025 | |
| Series A | $67M | Mar 2025 | |
| Series B | $59M | Jan 2025 | |
| HHillstar | Series A | $67M | Jan 2025 |
| MMaxion Therapeutics Ltd. | Series A | $72M | Jan 2025 |
| Series A | $27M | Dec 2024 | |
| Unknown | $12M | Oct 2024 | |
| Series A | $16M | Feb 2024 | |
| FFluid Biomed Inc | Series A | $27M | Jan 2024 |
| OOzlo | Unknown | $12M | Jan 2024 |
| OOxford Cancer Analytics (OXcan) | Seed | — | Jan 2023 |
| Seed | $16.5M | Dec 2021 | |
| Series B | $60M | May 2021 | |
| Series A | $80M | Jan 2021 | |
| Seed | $16.5M | Jan 2020 | |
| SSpringWorks | Series B | $125M | Jan 2019 |
| Series A | $103M | Jan 2017 | |
| Series A | — | — | |
| Seed | — | — | |
| Seed | — | — |
Top Co-Investors
Last updated: 8 September 2026